Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, Inc., has successfully completed the Phase IIb/IIIa clinical trial of its leading drug candidate for neurological and autoimmune disorders, RPI-78M, as a treatment for Adrenomyeloneuropathy (AMN).
“Completing this clinical trial is an important achievement for both Nutra Pharma and ReceptoPharm,” commented Paul Reid, CEO of ReceptoPharm. “Our next step is to compile, analyze and present the results from this trial to the medical community,” he concluded.
Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder that affects approximately 30,000 people worldwide. The disorder is characterized by the loss of the fatty covering (myelin sheath) on nerve fibers within the brain (cerebral demyelination) and the progressive degeneration of the adrenal gland (adrenal atrophy). Neurological disability in AMN is slowly progressive over several decades.
AMN interests the wider neurologic community because of its similarities to Multiple Sclerosis (MS). There is currently no approved treatment for AMN. Additionally, the disease's rarity designates it as an orphan drug candidate both in Europe and in the U.S. The Company has applied for Orphan drug status in the U.S. and intends doing so for the EU.
“Once the data from this trial has been presented, we will continue to expand ReceptoPharm’s clinical development program,” explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Currently, we are planning several additional clinical trials, including those for the treatment of Multiple Sclerosis using RPI-78M and the treatment of Rabies and HIV using RPI-MN,” he added.
ReceptoPharm expects to present the clinical findings from the study by the end of September.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The completion of the Phase IIa/IIIb clinical trial of RPI-78M for treating Adrenomyeloneuropathy should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.